Compare iShares Core S&P 500 ETF (IVV) vs Johnson & Johnson (JNJ) Price & Performance

iShares Core S&P 500 ETFTrade

Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Johnson & Johnson — how do they compare? iShares Core S&P 500 ETF trades at $782.09 (market cap $897.20B), while Johnson & Johnson trades at $260.67 (market cap $618.09B). The key difference: iShares Core S&P 500 ETF is the larger of the two by market cap, and Johnson & Johnson pays a 2.09% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Johnson & Johnson for 129 Days on average.

	IVV	JNJ
Market Cap	$897.20B	$618.09B
Volume	4,580,672	6,050,983
Sector	Broad Market / Factor	Health
52-Week High	$782.58	$278.43
52-Week Low	$634.93	$186.00
Typical Hold Time	46 Days	129 Days
Enterprise Value	—	$646.37B
Dividend Yield	—	2.09%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).

The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.

JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IVV

83% Buy17% Sell

Avg holding period · 46 Days

JNJ

82% Buy18% Sell

Avg holding period · 129 Days

Top news

Latest headlines on both assets

IVV

S&P 500 ETF outperformed mid-cap and dividend ETFs over 20 years, turning $10K into $92K.24/7 Wall Street · 4 days agoBullish View details →

JNJ

Johnson & Johnson Q3 earnings expected with 5% EPS drop but 5.8% revenue growthGordon Thompson · 8 hours agoNeutral Four Dividend Kings remain strong but PepsiCo's dividend payout is riskier than others.24/7 Wall Street · 11 hours agoNeutral New Phase 3 data show ICOTYDE provides lasting skin clearance in moderate-to-severe plaque psoriasis over two years.PRNewsWire · 12 hours agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.